Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Sep 21;42(36):3739-3740.
doi: 10.1093/eurheartj/ehab563.

Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure

Peter E Light  1
Affiliations
Editorial

Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure

Peter E Light. Eur Heart J. .
No abstract available

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Experimental design and major conclusions.
See this image and copyright information in PMC

Comment on

References

    1. Hsia DS, Grove O, Cefalu WT.. An update on sodium–glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2016; 24:73–79. - PMC - PubMed
    1. Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B.. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation 2019;139:1384–1395. - PMC - PubMed
    1. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammer A, Birkeland K, Jorgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium–Glucose Cotransporter-2 Inhibitors). Lower risk of heart failure and death in patients initiated on sodium–glucose cotransporter-2 inhibitors versus other glucose-lowering drugs. Circulation 2017;136:249–259. - PMC - PubMed
    1. Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barret TD, Shaw W, Desai M, Matthews DR, Neal B.. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 2018;138:458–468. - PMC - PubMed
    1. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019;139:2528–2536. - PubMed

MeSH terms

Substances

Grants and funding